Merck & Co., Inc. stock: Strategic acquisitions and oncology focus position shares for long-term value amid pipeline transitions

Merck & Co., Inc. (ISIN: US58933Y1055) advances its oncology leadership through the $6.7 billion Terns Pharmaceuticals acquisition, bolstering the pipeline ahead of Keytruda patent cliffs while delivering solid Q4 results and FY2026 guidance of $5.00–$5.15 EPS on the NYSE in USD.

Merck & Co., Inc. shares trade on the NYSE under the ticker MRK (ISIN: US58933Y1055) in USD, representing a cornerstone in the large-cap pharmaceuticals sector with a focus on oncology, vaccines, and animal health.

As of: 27.03.2026

By Elena Vasquez, Senior Financial Editor at NorthStar Market Insights: Merck & Co., Inc. exemplifies resilient pharmaceutical innovation, navigating blockbuster patent dynamics through targeted M&A in oncology.

Core Business Model and Market Leadership

Merck & Co., Inc. operates as a global healthcare company with three primary segments: Human Health Pharmaceutical, Human Health Animal Health, and Corporate.

The Human Health Pharmaceutical segment generates the bulk of revenue, driven by flagship products like Keytruda, an anti-PD-1 immunotherapy that dominates the oncology market.

Keytruda has established Merck as a leader in immuno-oncology, treating various cancers including melanoma, lung, and head and neck cancers, with sustained demand supporting revenue growth.

Complementing this, the Animal Health division provides vaccines, pharmaceuticals, and health management solutions for livestock and companion animals, offering diversification beyond human therapeutics.

Recent Strategic Acquisition of Terns Pharmaceuticals

Merck recently agreed to acquire Terns Pharmaceuticals for approximately $6.7 billion, or $53.00 per share, to incorporate TERN-701, an allosteric BCR-ABL1 inhibitor targeting chronic myeloid leukemia (CML).

Analysts view this as a strategic move to strengthen Merck's oncology pipeline, potentially offsetting risks from Keytruda's impending patent expiration.

The deal highlights Merck's commitment to M&A for pipeline replenishment, with TERN-701 seen as disruptive in CML treatment due to its novel mechanism.

Positive market reactions followed the announcement, with Terns shares climbing significantly, underscoring investor confidence in the transaction's value.

Financial Performance and Guidance

Merck reported Q4 revenues of $16.4 billion, surpassing estimates of $16.19 billion by 1.33%, with EPS of $2.04 beating expectations of $2.01.

Year-over-year, quarterly revenue grew 5.0%, and EPS improved from $1.72, reflecting operational strength.

For FY2026, Merck provided guidance of $5.00 to $5.15 EPS, alongside expectations of $66.68 billion in current fiscal year sales, up 2.6% year-over-year.

Next fiscal year sales are projected at $70.66 billion, a 6% increase, supporting a trajectory of steady growth.

Valuation Insights and Analyst Perspectives

Merck shares recently traded around $119 per share on the NYSE, with a 52-week range from $73.31 to $125.14.

A discounted cash flow analysis estimates an intrinsic value of $208.16 per share, suggesting the stock is undervalued by about 42.7% at current levels.

Analysts have raised price targets, including Citi to $125, Guggenheim to $140, Wells Fargo to $150, and RBC maintaining Outperform at $142.

The consensus reflects a mix of Buy and Hold ratings, with Zacks Rank #3 (Hold) based on earnings estimate trends.

Relevance for North American Investors

North American investors value Merck for its defensive qualities in healthcare portfolios, with Keytruda generating substantial U.S. revenue amid rising cancer incidence.

The company's 0.85 quarterly dividend yields around 2.8% annualized, appealing to income-focused strategies.

Balance sheet strength, evidenced by a current ratio of 1.54 and debt-to-equity of 0.89, supports sustained capital returns and R&D investment.

Exposure to U.S. market dynamics, including Medicare pricing and innovation incentives, directly influences Merck's performance for domestic holders.

Oncology Pipeline and Competitive Position

Merck's oncology franchise extends beyond Keytruda to include candidates like TERN-701, enhancing its position against rivals such as Bristol Myers Squibb and Roche.

Collaborations, such as the multi-year IBD target discovery with Quotient Therapeutics, signal proactive pipeline expansion into immunology.

The firm's return on equity of 44.57% and net margin of 28.08% underscore efficient operations in a competitive landscape.

Sector tailwinds, including aging populations and biologics demand, favor Merck's innovation-driven model.

Risks and Key Factors to Watch

Keytruda's patent cliff looms as a major risk, with generic competition potentially eroding peak sales post-exclusivity.

Current quarter EPS expectations of -$0.57 reflect seasonal or one-off pressures, with consensus estimates adjusting downward.

Regulatory hurdles for new assets like TERN-701 and broader pricing reforms could impact margins.

Investors should monitor Q1 earnings, acquisition integration progress, and oncology trial readouts for signals on growth sustainability.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.